Magellan Rx Pharmacy, LLC

CLOSEOUT LETTER Magellan Rx Pharmacy, LLC MARCS-CMS 536134 — June 06, 2019 More Warning Letters Warning Letters About Warning and Close-Out Letters Product: Drugs Recipient: Recipient Name Steffanie M. Mathewson Recipient Title Senior Legal Counsel Magellan Rx Pharmacy, LLC 55 Nod Road Avon , CT 06001 United States Issuing Office: Division of Pharmaceutical Quality Operations I 10 Waterview Blvd 3rd FL Parsippany , NJ 07054 United States (973) 331-4900 Dear Ms. Mathewson: The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter (WL # 536134) dated September 11, 2017. We acknowledge that your Astoria, New York, facility has closed, effective December 31, 2018, and relinquished its New York State Pharmacy License when the facility closed. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter. You are expected to take all necessary steps to assure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations, should your facility re-open. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means. Send your electronic response or request to orapharm1_responses@fda.hhs.gov . Please identify your response or related request with FEI #3012729025. If you have any questions, contact Compliance Officer Juan Jimenez at juan.jimenez@fda.hhs.gov or 518-453-2314 X-1014. /S/ Stephanie Durso Director Compliance Branch U.S. Food and Drug Administration OPQO Division I / New Jersey District Content current as of: 02/03/2020 Regulated Product(s) Drugs